Search
for
Sort by
Research 31–60 of 1000+
- 080 Mouse models of alopecia areata: C3H/HeJ mice versus the humanized AA mouse model
- Eosinophilia versus atopy as a predictor of severe phenotypes in alopecia areata
- 75392 Psychosocial Burden of Severe Pediatric Alopecia Areata and Strategies for Mitigation: A Narrative Evidence Synthesis
- Idiopathic Alopecia—A Retrospective Descriptive Study Integrated with the Current Literature
- When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials
- Treatment of severe alopecia areata with oral tofacitinib: A case series
- 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
- Alefacept for Severe Alopecia Areata
- Treatment of severe alopecia areata with baricitinib
- Diagnostic Exercise: Severe Bilaterally Symmetrical Alopecia in a Horse
- Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
- Ex Vivo Treatment with Allogenic Mesenchymal Stem Cells of a Healthy Donor on Peripheral Blood Mononuclear Cells of Patients with Severe Alopecia Areata: Targeting Dysregulated T Cells and the Acquisition of Immunotolerance
- Upadacitinib for Severe Alopecia Areata in Adults and Adolescents
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
- Diphenylcyclopropenone in severe alopecia areata in children and adolescents: long-term follow-up and relapse rate
- Patient-Reported Burden of Severe Alopecia Areata: First Results from the Multinational Alopecia Areata Unmet Need Survey
- Tofacitinib treatment in a severe pediatric alopecia areata: A case report and a literature review
- Successful management of severe alopecia areata and vitiligo using topical delgocitinib and a 308-nm excimer laser
- Treatment of moderate-to-severe alopecia areata in adolescents with baricitinib: A retrospective review of 29 patients
- Partial Response of Severe Alopecia areata to Cyclosporine A
- Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
- Low-Dose IL-2 for Treating Moderate to Severe Alopecia Areata: A 52-Week Multicenter Prospective Placebo-Controlled Study Assessing its Impact on T Regulatory Cell and NK Cell Populations
- Early Intervention with High-Dose Steroid Pulse Therapy Prolongs Disease-Free Interval of Severe Alopecia Areata: A Retrospective Study
- Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
- Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials
- How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
- Unique Circulating MicroRNA Signatures Distinguish Severe Alopecia Areata from Other Inflammatory Skin Diseases